Kidron Nadavinsider trades
In SEC Form 4 filings, Kidron Nadav is listed as President and CEO of Oramed Pharmaceuticals Inc. (ORMP) and Director of Nano Dimension Ltd. (NNDM). Kidron Nadav reported no open-market purchases or sales in the last 90 days. The latest Form 4 transaction on record was filed on Sep 25.
Companies and roles
Cluster buys
No cluster buy in the last 90 days included a purchase by this insider (two or more insiders buying within 14 days).
Form 4 historysince 2026-08-25
| Company | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| ORMPOramed Pharmaceuticals Inc. | Sep 24 | Sep 25 | A | 349,497 | not reported | not reported | 3,771,740 | No | Form 4 |
| ORMPOramed Pharmaceuticals Inc. | Sep 24 | Sep 25 | A | 368,765 | not reported | not reported | 4,140,505 | No | Form 4 |
| ORMPOramed Pharmaceuticals Inc. | Sep 24 | Sep 25 | D · derivative | 196,500 | $3.16 | $620,940 | not reported | No | Form 4 |
| ORMPOramed Pharmaceuticals Inc. | Sep 24 | Sep 25 | D · derivative | 190,000 | $4.80 | $912,000 | not reported | No | Form 4 |
| ORMPOramed Pharmaceuticals Inc. | Sep 24 | Sep 25 | D · derivative | 49,000 | $7.77 | $380,730 | not reported | No | Form 4 |
| ORMPOramed Pharmaceuticals Inc. | Sep 24 | Sep 25 | D · derivative | 97,000 | $8.14 | $789,580 | not reported | No | Form 4 |
| ORMPOramed Pharmaceuticals Inc. | Sep 24 | Sep 25 | D · derivative | 150,000 | $10.40 | $1,560,000 | not reported | No | Form 4 |
| ORMPOramed Pharmaceuticals Inc. | Sep 24 | Sep 25 | D · derivative | 107,000 | $13.89 | $1,486,230 | not reported | No | Form 4 |
| NNDMNano Dimension Ltd. | Aug 21 | Aug 25 | X | 10,000 | $1.50 | $15,000 | 30,000 | No | Form 4 |
| NNDMNano Dimension Ltd. | Aug 21 | Aug 25 | X · derivative | 100 | $1.50 | $150 | not reported | No | Form 4 |
Published from this insider's public Form 4 filings on SEC EDGAR; the name is shown as filed. Named in a filing and want this page removed? See the privacy policy.